187 related articles for article (PubMed ID: 31432744)
1. NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy.
Hansen CR; Friborg J; Jensen K; Samsøe E; Johnsen L; Zukauskaite R; Grau C; Maare C; Johansen J; Primdahl H; Bratland Å; Kristensen CA; Andersen M; Eriksen JG; Overgaard J
Acta Oncol; 2019 Oct; 58(10):1410-1415. PubMed ID: 31432744
[No Abstract] [Full Text] [Related]
2. Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort.
Blanchard P; Wong AJ; Gunn GB; Garden AS; Mohamed ASR; Rosenthal DI; Crutison J; Wu R; Zhang X; Zhu XR; Mohan R; Amin MV; Fuller CD; Frank SJ
Radiother Oncol; 2016 Dec; 121(3):381-386. PubMed ID: 27641784
[TBL] [Abstract][Full Text] [Related]
3. External validation of a multifactorial normal tissue complication probability model for tube feeding dependence at 6 months after definitive radiotherapy for head and neck cancer.
Kanayama N; Kierkels RGJ; van der Schaaf A; Steenbakkers RJHM; Yoshioka Y; Nishiyama K; Fujii T; Ogawa K; Langendijk JA; Teshima T
Radiother Oncol; 2018 Nov; 129(2):403-408. PubMed ID: 30301559
[TBL] [Abstract][Full Text] [Related]
4. NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy.
Jakobi A; Stützer K; Bandurska-Luque A; Löck S; Haase R; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
Acta Oncol; 2015; 54(9):1658-64. PubMed ID: 26340301
[TBL] [Abstract][Full Text] [Related]
5. Physical and Radiobiological Evaluation of Accelerated Intensity Modulated Radiotherapy for Locally Advanced Head and Neck Cancer and Comparison with Short-Term Clinical Outcomes.
Buchapudi RR; Manickam R; M R AK; C R TP; Chandraraj V; Pyakuryal A; Narayanasamy G
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2463-2470. PubMed ID: 31450921
[TBL] [Abstract][Full Text] [Related]
6. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma.
Saksø M; Andersen E; Bentzen J; Andersen M; Johansen J; Primdahl H; Overgaard J; Eriksen JG
Acta Oncol; 2019 Oct; 58(10):1495-1501. PubMed ID: 31519130
[No Abstract] [Full Text] [Related]
7. Considerations for study design in the DAHANCA 35 trial of protons versus photons for head and neck cancer.
Friborg J; Jensen K; Eriksen JG; Samsøe E; Maare C; Farhadi M; Sibolt P; Nielsen M; Andersen M; Holm AIS; Skyt P; Smulders B; Johansen J; Overgaard J; Grau C; Hansen CR
Radiother Oncol; 2024 Jan; 190():109958. PubMed ID: 37871751
[TBL] [Abstract][Full Text] [Related]
8. Normal tissue complication probability models in plan evaluation of children with brain tumors referred to proton therapy.
Stokkevåg CH; Indelicato DJ; Herfarth K; Magelssen H; Evensen ME; Ugland M; Nordberg T; Nystad TA; Hægeland C; Alsaker MD; Ulven K; Dale JE; Engeseth GM; Boer CG; Toussaint L; Kornerup JS; Pettersen HES; Brydøy M; Brandal P; Muren LP
Acta Oncol; 2019 Oct; 58(10):1416-1422. PubMed ID: 31364899
[No Abstract] [Full Text] [Related]
9. A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer.
Rwigema JM; Langendijk JA; Paul van der Laan H; Lukens JN; Swisher-McClure SD; Lin A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):553-562. PubMed ID: 30625409
[TBL] [Abstract][Full Text] [Related]
10. Protons in head-and-neck cancer: bridging the gap of evidence.
Ramaekers BL; Grutters JP; Pijls-Johannesma M; Lambin P; Joore MA; Langendijk JA
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1282-8. PubMed ID: 23273998
[TBL] [Abstract][Full Text] [Related]
11. Optimal Allocation of Proton Therapy Slots in Combined Proton-Photon Radiation Therapy.
Loizeau N; Fabiano S; Papp D; Stützer K; Jakobi A; Bandurska-Luque A; Troost EGC; Richter C; Unkelbach J
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):196-207. PubMed ID: 33848609
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of decentralised model-based selection of head and neck cancer patients for a proton treatment study. DAHANCA 35.
Hansen CR; Jensen K; Smulders B; Holm AIS; Samsøe E; Nielsen MS; Sibolt P; Skyt P; Elstrøm UV; Nielsen CP; Johansen J; Zukauskaite R; Eriksen JG; Farhadi M; Andersen M; Andersen E; Overgaard J; Grau C; Friborg J
Radiother Oncol; 2024 Jan; 190():109812. PubMed ID: 37479061
[TBL] [Abstract][Full Text] [Related]
13. Swallowing sparing intensity modulated radiotherapy (SW-IMRT) in head and neck cancer: Clinical validation according to the model-based approach.
Christianen ME; van der Schaaf A; van der Laan HP; Verdonck-de Leeuw IM; Doornaert P; Chouvalova O; Steenbakkers RJ; Leemans CR; Oosting SF; van der Laan BF; Roodenburg JL; Slotman BJ; Bijl HP; Langendijk JA
Radiother Oncol; 2016 Feb; 118(2):298-303. PubMed ID: 26700602
[TBL] [Abstract][Full Text] [Related]
14. Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis.
Jakobi A; Bandurska-Luque A; Stützer K; Haase R; Löck S; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1165-1174. PubMed ID: 26194685
[TBL] [Abstract][Full Text] [Related]
15. Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia.
Yahya N; Linge A; Leger K; Maile T; Kemper M; Haim D; Jöhrens K; Troost EGC; Krause M; Löck S
Acta Oncol; 2022 Jul; 61(7):856-863. PubMed ID: 35657056
[TBL] [Abstract][Full Text] [Related]
16. Patient selection for proton therapy using Normal Tissue Complication Probability with deep learning dose prediction for oropharyngeal cancer.
Huet-Dastarac M; Michiels S; Rivas ST; Ozan H; Sterpin E; Lee JA; Barragan-Montero A
Med Phys; 2023 Oct; 50(10):6201-6214. PubMed ID: 37140481
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Carboplatin/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck.
Maring S; Elsayad K; Stenner M; Rudack C; Haverkamp U; Rehkämper J; Wardelmann E; Eich HT
Oncol Res Treat; 2018; 41(12):736-743. PubMed ID: 30419553
[TBL] [Abstract][Full Text] [Related]
18. Volumetric changes in pharyngeal structures following head and neck cancer chemoradiation therapy.
Hinther A; Samson N; Lau H; Quon H; Banerjee R; Lysack JT; Grendarova P; Matthews TW; Randall DR
Laryngoscope; 2020 Mar; 130(3):597-602. PubMed ID: 31260128
[TBL] [Abstract][Full Text] [Related]
19. The Quest for Evidence for Proton Therapy: Model-Based Approach and Precision Medicine.
Widder J; van der Schaaf A; Lambin P; Marijnen CAM; Pignol JP; Rasch CR; Slotman BJ; Verheij M; Langendijk JA
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):30-36. PubMed ID: 26684410
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of long term (10-years+) dysphagia and trismus in patients treated with concurrent chemo-radiotherapy for advanced head and neck cancer.
Kraaijenga SA; Oskam IM; van der Molen L; Hamming-Vrieze O; Hilgers FJ; van den Brekel MW
Oral Oncol; 2015 Aug; 51(8):787-94. PubMed ID: 26027851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
